RENOVUE-65 Drug Patent Profile
✉ Email this page to a colleague
When do Renovue-65 patents expire, and when can generic versions of Renovue-65 launch?
Renovue-65 is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in RENOVUE-65 is iodamide meglumine. There is one drug master file entry for this compound. Additional details are available on the iodamide meglumine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RENOVUE-65?
- What are the global sales for RENOVUE-65?
- What is Average Wholesale Price for RENOVUE-65?
Summary for RENOVUE-65
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| Patent Applications: | 34 |
| DailyMed Link: | RENOVUE-65 at DailyMed |
US Patents and Regulatory Information for RENOVUE-65
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | RENOVUE-65 | iodamide meglumine | INJECTABLE;INJECTION | 017902-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
